More than seizures: improving the lives of people with refractory epilepsy
M. Mula
Atkinson Morley Epilepsy Group, St Georges NHS Trust, London, UK
St George's University of London, London, UK
Search for more papers by this authorCorresponding Author
H. R. Cock
Atkinson Morley Epilepsy Group, St Georges NHS Trust, London, UK
St George's University of London, London, UK
Correspondence: H. Cock, Atkinson Morley Epilepsy Group, St Georges NHS Trust, Blackshaw Road, London SW17 0QT, UK (tel.: +44 20 8725 2002; fax: +44 20 8181 6897; e-mail: [email protected]). Search for more papers by this authorM. Mula
Atkinson Morley Epilepsy Group, St Georges NHS Trust, London, UK
St George's University of London, London, UK
Search for more papers by this authorCorresponding Author
H. R. Cock
Atkinson Morley Epilepsy Group, St Georges NHS Trust, London, UK
St George's University of London, London, UK
Correspondence: H. Cock, Atkinson Morley Epilepsy Group, St Georges NHS Trust, Blackshaw Road, London SW17 0QT, UK (tel.: +44 20 8725 2002; fax: +44 20 8181 6897; e-mail: [email protected]). Search for more papers by this authorAbstract
As captured by the proposed new definition, epilepsy is increasingly recognized as a disorder characterized not only by an enduring predisposition to recurrent seizures but explicitly also by the neurobiological, cognitive, psychological and social consequences of this condition. Further, both in the estimated 15 million people worldwide who have ongoing seizures despite optimal management and in a substantial proportion of those in remission, the consequences and comorbidities of epilepsy are the major determinants of quality of life. These include mood disorders such as anxiety and depression, dose related and longer term effects of antiepileptic drugs, including on prenatal development and bone health, and neurobehavioural effects. Whilst separating those that are part of an underlying condition or have unrelated contributors from those that are potentially remediable can be difficult, given the range of tools now available to assist with screening and management there is no excuse for not at least trying as part of standard care for people with epilepsy. Managing epilepsy well is about much more than controlling seizures and this needs to be recognized in planning and delivering services, as well as in prioritizing research.
References
- 1Banerjee PN, Filippi D, Hauser WA. The descriptive epidemiology of epilepsy − a review. Epilepsy Res 2009; 85: 31–45.
- 2Fisher RS, Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46: 470–472.
- 3Birbeck GL, Hays RD, Cui XP, Vickrey BG. Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 2002; 43: 535–538.
- 4Schmidt D, Schachter SC. Drug treatment of epilepsy in adults. BMJ 2014; 348: g254.
- 5Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects – a randomized trial. Neurology 2004; 62: 23–27.
- 6Kerr MP, Mensah S, Besag F, et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia 2011; 52: 2133–2138.
- 7Danquah-Boateing D, Cock HR. Bone health advice in an adult epilepsy service: re-audit of practice and influence of national guidance. J Neurol 2014; 261: S387.
- 8Taylor RS, Sander JW, Taylor RJ, Baker GA. Predictors of health-related quality of life and costs in adults with epilepsy: a systematic review. Epilepsia 2011; 52: 2168–2180.
- 9Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry 2014; 85: 1029–1034.
- 10Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy: results from the UK and Ireland Epilepsy and Pregnancy Registers. Neurology 2013; 80: 400–405.
- 11Gentile S. Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions. CNS Spectr 2014; 19: 305–315.
- 12Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2006; 369: 1016–1026.
- 13Vestergaard P. Epilepsy, osteoporosis and fracture risk − a meta-analysis. Acta Neurol Scand 2005; 112: 277–286.
- 14Ahmad BS, Hill KD, O'Brien TJ, Gorelik A, Habib N, Wark JD. Falls and fractures in patients chronically treated with antiepileptic drugs. Neurology 2012; 79: 145–151.
- 15Souverein PC, Webb DJ, Weil JG, Van Staa P, Egberts ACG. Use of antiepileptic drugs and risk of fractures – case−control study among patients with epilepsy. Neurology 2006; 66: 1318–1324.
- 16Pack AM. Treatment of epilepsy to optimize bone health. Curr Treat Options Neurol 2011; 13: 346–354.
- 17Shellhaas RA, Barks AK, Joshi SM. Prevalence and risk factors for vitamin D insufficiency among children with epilepsy. Pediatr Neurol 2010; 42: 422–426.
- 18Kumar J, Muntner P, Kaskel FJ, Hailpern SM, Melamed ML. Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001–2004. Pediatrics 2009; 124: e362–e370.
- 19Mikati MA, Dib L, Yamout B, Sawaya R, Rahi AC, Fuleihan GEH. Two randomized vitamin D trials in ambulatory patients on anticonvulsants – impact on bone. Neurology 2006; 67: 2005–2014.
- 20 MHRA. Antiepileptics: adverse effects on bone. Drug Safety Update 2009; 2: 2.
- 21Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. Br Med J 2012; 344: 1–16.
- 22Francis R, Aspray T, Fraser W, et al. Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management. Bath, UK: National Osteoporosis Society, 2013.
- 23Lazzari AA, Dussault PM, Thakore-James M, et al. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy − antiepileptic drug and osteoporosis prevention trial. Epilepsia 2013; 54: 1997–2004.
- 24Elliott JO, Jacobson MP, Seals BF. Self-efficacy, knowledge, health beliefs, quality of life, and stigma in relation to osteoprotective behaviors in epilepsy. Epilepsy Behav 2006; 9: 478–491.
- 25Wasade VS, Spanaki M, Iyengar R, Barkley GL, Schultz L. AAN epilepsy quality measures in clinical practice: a survey of neurologists. Epilepsy Behav 2012; 24: 468–473.
- 26Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet 2012; 380: 1180–1192.
- 27Tellez-Zenteno JF, Patten SB, Jette N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007; 48: 2336–2344.
- 28Quiske A, Helmstaedter C, Lux S, Elger CE. Depression in patients with temporal lobe epilepsy is related to mesial temporal sclerosis. Epilepsy Res 2000; 39: 121–125.
- 29Perucca P, Mula M. Antiepileptic drug effects on mood and behavior: molecular targets. Epilepsy Behav 2013; 26: 440–449.
- 30Boylan LS, Flint LA, Labovitz DL, Jackson SC, Starner K, Devinsky O. Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. Neurology 2004; 62: 258–261.
- 31Cramer JA, Blum D, Reed M, Fanning K. The influence of comorbid depression on seizure severity. Epilepsia 2003; 44: 1578–1584.
- 32Hitiris N, Mohanraj R, Norrie J, Brodie MJ. Mortality in epilepsy. Epilepsy Behav 2007; 10: 363–376.
- 33Kanner AM. Depression in epilepsy: a complex relation with unexpected consequences. Curr Opin Neurol 2008; 21: 190–194.
- 34Mintzer S, Lopez F. Comorbidity of ictal fear and panic disorder. Epilepsy Behav 2002; 3: 330–337.
- 35Krishnamoorthy ES. The evaluation of behavioral disturbances in epilepsy. Epilepsia 2006; 47(Suppl 2): 3–8.
- 36Gilliam FG, Barry JJ, Hermann BP, Meador KJ, Vahle V, Kanner AM. Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol 2006; 5: 399–405.
- 37Rampling JR, Mitchell AJ, Von Oertzen J, et al. Screening for depression in epilepsy clinics: a comparison of conventional and visual analogue methods. Epilepsia 2012; 53: 1713–1721.
- 38Gur-Ozmen S, Cock HR, Agrawal N, Von Oertzen J. Screening for anxiety in epilepsy clinics. A comparison of conventional and visual-analog methods. J Neurol 2014; 261: S63.
- 39Jones JE, Hermann BP, Woodard JL, et al. Screening for major depression in epilepsy with common self-report depression inventories. Epilepsia 2005; 46: 731–735.
- 40Blumer D, Montouris G, Davies K, Wyler A, Phillips B, Hermann B. Suicide in epilepsy: psychopathology, pathogenesis, and prevention. Epilepsy Behav 2002; 3: 232–241.
- 41Mula M, Jauch R, Cavanna A, et al. Clinical and psychopathological definition of the interictal dysphoric disorder of epilepsy. Epilepsia 2008; 49: 650–656.
- 42Mula M, Kanner AM. Introduction − Treatment of psychiatric disorders in adults with epilepsy: what every epileptologist should know. Epilepsia 2013; 54(Suppl 1): 1–2.
- 43Barry JJ, Ettinger AB, Friel P, et al. Consensus statement: The evaluation and treatment of people with epilepsy and affective disorders. Epilepsy Behav 2008; 13(Suppl 1): S1–S29.
- 44Mula M. Treatment of anxiety disorders in epilepsy: an evidence-based approach. Epilepsia 2013; 54(Suppl 1): 13–18.
- 45Kanner AM. The treatment of depressive disorders in epilepsy: what all neurologists should know. Epilepsia 2013; 54: 3–12.
- 46Mula M. Anticonvulsants – antidepressants pharmacokinetic drug interactions: the role of the CYP450 system in psychopharmacology. Curr Drug Metab 2008; 9: 730–737.
- 47Mula M. Recognize and manage psychiatric comorbidities in patients with epilepsy. Panminerva Med 2011; 53: 241–251.
- 48Mula M, Monaco F, Trimble MR. Use of psychotropic drugs in patients with epilepsy: interactions and seizure risk. Expert Rev Neurother 2004; 4: 953–964.
- 49Mula M, Schmitz B, Sander JW. The pharmacological treatment of depression in adults with epilepsy. Expert Opin Pharmacother 2008; 9: 3159–3168.
- 50Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007; 62: 345–354.
- 51Crail-Melendez D, Herrera-Melo A, Martinez-Juarez IE, Ramirez-Bermudez J. Cognitive-behavioral therapy for depression in patients with temporal lobe epilepsy: a pilot study. Epilepsy Behav 2012; 23: 52–56.
- 52Martinovic Z. Adjunctive behavioural treatment in adolescents and young adults with juvenile myoclonic epilepsy. Seizure 2001; 10: 42–47.
- 53de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav 2008; 12: 540–546.
- 54Kerr MP, Turky A, Huber B. The psychosocial impact of epilepsy in adults with an intellectual disability. Epilepsy Behav 2009; 15(Suppl 1): S26–S30.
- 55Meador KJ. Cognitive and memory effects of the new antiepileptic drugs. Epilepsy Res 2006; 68: 63–67.
- 56Mula M, Trimble MR. Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. CNS Drugs 2009; 23: 121–137.
- 57Avanzini G, Depaulis A, Tassinari A, de Curtis M. Do seizures and epileptic activity worsen epilepsy and deteriorate cognitive function? Epilepsia 2013; 54(Suppl 8): 14–21.
- 58Giovagnoli AR, Canafoglia L, Reati F, Ravaglione F, Franceschetti S. The neuropsychological pattern of Unverricht−Lundborg disease. Epilepsy Res 2009; 84: 217–223.
- 59Ferlazzo E, Gagliano A, Calarese T, et al. Neuropsychological findings in patients with Unverricht−Lundborg disease. Epilepsy Behav 2009; 14: 545–549.
- 60Billard C, Fluss J, Pinton F. Specific language impairment versus Landau−Kleffner syndrome. Epilepsia 2009; 50(Suppl 7): 21–24.
- 61Wolff M, Cassé-Perrot C, Dravet C. Severe myoclonic epilepsy of infants (Dravet syndrome): natural history and neuropsychological findings. Epilepsia 2006; 47(Suppl 2): 45–48.
- 62Siegel MS, Smith WE. Psychiatric features in children with genetic syndromes: toward functional phenotypes. Child Adolesc Psychiatr Clin N Am 2010; 19: 229–261.
- 63Tassinari CA, Cantalupo G, Rios-Pohl L, Giustina ED, Rubboli G. Encephalopathy with status epilepticus during slow sleep: ‘the Penelope syndrome’. Epilepsia 2009; 50(Suppl 7): 4–8.
- 64Mula M. Recent and future antiepileptic drugs and their impact on cognition: what can we expect? Expert Rev Neurother 2012; 12: 667–671.
- 65Thompson PJ, Trimble MR. Changing to one anticonvulsant. Lancet 1981; 1: 447.
- 66Trimble MR, Thompson PJ. Memory, anticonvulsant drugs and seizures. Acta Neurol Scand Suppl 1981; 89: 31–41.
- 67Canevini MP, De Sarro G, Galimberti CA, et al. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia 2010; 51: 797–804.
- 68Trimble MR. Anticonvulsant drugs and cognitive function: a review of the literature. Epilepsia 1987; 28(Suppl 3): S37–S45.